Clinical Trial

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

Study acronym: CompARE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2019-10-03; most recent amendment 2026-04-30.
Status change: Recruiting → Active, Not Recruiting 2024-05-07
Trial Details
NCT Number NCT04116047
Lead Sponsor University of Birmingham
Collaborators: AstraZeneca, Cancer Trials Ireland
Conditions Oropharyngeal Cancer
Enrollment 785 participants
Start Date 2015-07
Primary Completion 2026-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-07